Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Janssen acquires Cerecor compound

by Michael McCoy
August 20, 2017 | A version of this story appeared in Volume 95, Issue 33

Janssen Pharmaceuticals has acquired the selective kappa opioid receptor antagonist CERC-501 from Cerecor for $25 million plus a possible $20 million milestone payment. Baltimore-based Cerecor acquired CERC-501 from Eli Lilly & Co. in early 2015 and was developing the drug as a treatment for depression and substance use disorders. Late last year, Cerecor announced that CERC-501 failed in a trial as a treatment for nicotine withdrawal.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.